Chronic Hepatitis B and Pregnancy: Management and Prevention of Vertical Transmission

5 (1 vote)

Recorded On: 09/14/2017

The management of women of child-bearing age and pregnant women with chronic hepatitis B requires special consideration due to the potential effects of antiviral therapy on unborn fetus and potential for hepatitis flares for pregnant and postpartum women. While universal maternal screening programs and immunoprophylaxis to newborns have greatly reduced mother-to-child-transmission (MTCT), immunoprophylaxis can fail in up to 30% of infants, especially in mothers with high HBV DNA levels and positive HBeAg. As a result, there has been growing support for the initiation of antiviral therapy during late pregnancy in highly viremic women, and this has been shown in a recent randomized controlled trial to be safe and effective in preventing MTCT with antiviral therapy starting at 30-week gestation and in combination with birth-dose HBV immunoglobulin (HBIG) and vaccination followed by completion of the 3-dose vaccine series.  

Mindie H. Nguyen (Moderator)

Dr. Nguyen is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

Tram T. Tran

Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

Calvin Q. Pan

Calvin Pan, MD is Clinical Professor of Medicine at the Division of Gasteroenterology and Hepatology in NYU Langone Medical Center in New York. Dr. Pan currently chairs the Online Learning Committee of AASLD. His research interest is a focus on the natural history of viral hepatitis, antiviral therapy and the prevention of vertical transmission of hepatitis virus. As the leading author, Dr. Pan has presented original articles in many high impact journals including the New England Journal of Medicine and Hepatology. He is the recipient of the Mastership Award from the American College of Physicians.

Components visible upon registration.